“非处方药不列入医保目录规定遭受的阻力比较大,实施有难度。”国家药监局的一位人士私下透露。不久前,将上升为全国性法规的《处方药与非处方药分类管理条例》(草案)(以下简称《条例》)在提交国务院法制办前,最后一次征求中国非处方药协会、中国化学制药工业协会与企业意见时 “Non-prescription drugs are not included in the Medicare directory provisions of the resistance suffered relatively large, difficult to implement.” A SFDA official said privately. Not long ago, the Regulations on the Classification and Administration of Prescription Drugs and Non-Prescription Drugs (hereinafter referred to as “the Regulations”), which will rise to the national laws and regulations, sought the final opinion of the China Non-Prescription Medicine Association, China National Chemical and Pharmaceutical Industry Association and the enterprises before submission to the Legal Affairs Office of the State Council Time